Adaptive Biotechnologies Corporation

41.33-0.7000-1.67%Vol 565.70K1Y Perf 46.93%
Apr 19th, 2021 16:00 DELAYED
BID40.99 ASK41.95
Open41.25 Previous Close42.03
Pre-Market- After-Market-
 - -  - -%
Target Price
61.80 
Analyst Rating
Strong Buy 1.00
Potential %
49.53 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.59
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★     54.82
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap5.75B 
Earnings Rating
Price Range Ratio 52W %
31.95 
Earnings Date
5th May 2021

Today's Price Range

40.2342.39

52W Range

27.2871.25

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-4.75%
1 Month
-1.34%
3 Months
-38.18%
6 Months
-14.31%
1 Year
46.93%
3 Years
-
5 Years
-36.59%
10 Years
-

TickerPriceChg.Chg.%
ADPT41.33-0.7000-1.67
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.30-0.33-10.00
Q03 2020-0.28-0.273.57
Q02 2020-0.30-0.2613.33
Q01 2020-0.22-0.25-13.64
Q04 2019-0.16-0.17-6.25
Q03 2019-0.17-0.1135.29
Q02 2019-0.15-1.23-720.00
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date5th May 2021
Estimated EPS Next Report-0.41
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume565.70K
Shares Outstanding139.22M
Trades Count8.90K
Dollar Volume92.77M
Avg. Volume1.01M
Avg. Weekly Volume683.50K
Avg. Monthly Volume986.22K
Avg. Quarterly Volume1.03M

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock closed at 41.33 per share at the end of the most recent trading day (a -1.67% change compared to the prior day closing price) with a volume of 599.17K shares and market capitalization of 5.75B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 622 people. Adaptive Biotechnologies Corporation CEO is Chad Robins.

The one-year performance of Adaptive Biotechnologies Corporation stock is 46.93%, while year-to-date (YTD) performance is -30.1%. ADPT stock has a five-year performance of -36.59%. Its 52-week range is between 27.28 and 71.25, which gives ADPT stock a 52-week price range ratio of 31.95%

Adaptive Biotechnologies Corporation currently has a PE ratio of -38.20, a price-to-book (PB) ratio of 7.87, a price-to-sale (PS) ratio of 74.27, a price to cashflow ratio of 10.80, a PEG ratio of 2.32, a ROA of -13.86%, a ROC of -18.35% and a ROE of -21.43%. The company’s profit margin is -93.01%, its EBITDA margin is -134.80%, and its revenue ttm is $77.47 Million , which makes it $0.56 revenue per share.

Of the last four earnings reports from Adaptive Biotechnologies Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Adaptive Biotechnologies Corporation’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for Adaptive Biotechnologies Corporation is Strong Buy (1), with a target price of $61.8, which is +49.53% compared to the current price. The earnings rating for Adaptive Biotechnologies Corporation stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adaptive Biotechnologies Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adaptive Biotechnologies Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 18.97, ATR14 : 3.77, CCI20 : 21.01, Chaikin Money Flow : -0.04, MACD : -4.97, Money Flow Index : 56.51, ROC : 2.66, RSI : 34.12, STOCH (14,3) : 61.60, STOCH RSI : 0.69, UO : 46.85, Williams %R : -38.40), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adaptive Biotechnologies Corporation in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
6 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

CEO: Chad Robins

Telephone: +1 206 659-0067

Address: 1551 Eastlake Avenue East, Seattle 98102, WA, US

Number of employees: 622

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

59%41%

Bearish Bullish

55%45%

Bearish Bullish

62%38%

News

Stocktwits